Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 148 clinical trials
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

ravulizumab in adult participants with dermatomyositis (DM).

corticosteroids
dermatomyositis
rituximab
azathioprine
methotrexate
  • 2 views
  • 02 May, 2022
  • 20 locations
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (RECLAIIM)

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of

myopathy
corticosteroids
a 10
dermatomyositis
prednisolone
  • 35 views
  • 17 Feb, 2022
  • 59 locations
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

>Juvenile Dermatomyositis (JDM)

dermatomyositis
prednisone
pulmonary disease
rheumatism
hydroxychloroquine
  • 43 views
  • 12 May, 2022
  • 14 locations
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) (ISLAND-SLE)

The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).

antinuclear antibody
arthritis
rash
lupus
  • 179 views
  • 30 Apr, 2022
  • 111 locations
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies.

arthritis
mycophenolate
chloroquine
prednisone
antinuclear antibody
  • 97 views
  • 23 May, 2022
  • 128 locations
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

corticosteroids
mycophenolate
azathioprine
antimalarials
methotrexate
  • 232 views
  • 24 May, 2022
  • 124 locations
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

corticosteroids
sjogren's syndrome
antinuclear antibody
immunosuppressive agents
rheumatism
  • 189 views
  • 27 May, 2022
  • 214 locations
COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL (CRISP)

The COVID-19 pandemic represents a threat to rheumatology patients. National advice for patients to 'shield' is based on risk stratification of therapies and other risk factors. While the epidemiology of COVID-19 in the rheumatological population is largely unknown large case registries are beginning to show potential drug treatment interactions. Strict …

  • 0 views
  • 24 Mar, 2022
  • 1 location
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

arthritis
rheumatism
calcium channel blockers
myositis
calcium
  • 0 views
  • 22 Mar, 2022
  • 12 locations
Study of M5049 in CLE and SLE Participants

This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).

lupus
cutaneous lupus
  • 0 views
  • 10 May, 2022
  • 9 locations